Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 and 6) are approved for the treatment of subsets of patients with hormone receptor positive (HR+) breast cancer (BC). In metastatic disease, strategies involving endocrine therapy combined with CDK4 and 6 inhibitors (CDK4 and 6i) imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wander, Seth A, O’Brien, Neil, Litchfield, Lacey M, O’Dea, Declan, Morato Guimaraes, Claudia, Slamon, Dennis J, Goel, Shom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Academia-Pharma Intersect
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526495/
https://www.ncbi.nlm.nih.gov/pubmed/35917168
http://dx.doi.org/10.1093/oncolo/oyac138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526495/
https://www.ncbi.nlm.nih.gov/pubmed/35917168
http://dx.doi.org/10.1093/oncolo/oyac138

Ejemplares similares